Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 2Neoplasms 2Thoracic Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Lymphoma, Large B-Cell, Diffuse 1Locally Advanced or Metastatic Solid Tumors 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Breast Neoplasms 1

Interventions

Carboplatin 27Paclitaxel 23Cisplatin 22Gemcitabine 17pembrolizumab 15Fluorouracil 9Pemetrexed 8Everolimus 8Docetaxel 8Cetuximab 8Radiotherapy, Intensity-Modulated 7Radiotherapy 7130-nm albumin-bound paclitaxel 7Sorafenib 6Nivolumab 6Bevacizumab 6Axitinib 6epothilone B 5Sunitinib 5Radiation 5Panitumumab 5Cyclophosphamide 5trebananib 4reolysin 4padeliporfin 4lenvatinib 4Irinotecan 4Gefitinib 4vosaroxin 3volociximab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoma × efineptakin alfa × Clear all
NCT04332653 2026-03-09

NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

NeoImmuneTech

Phase 1/2 Completed
215 enrolled 30 charts
BreastGastrointestinalGynecologicThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Thoracic Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡